Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
Public ClinicalTrials.gov record NCT00362856. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Study identification
- NCT ID
- NCT00362856
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- 9 Meters Biopharma, Inc.
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- larazotide acetate Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 12, 2006
- Primary completion
- Mar 5, 2007
- Completion
- Mar 5, 2007
- Last update posted
- Sep 11, 2017
2006 – 2007
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85259 | — |
| Not listed | San Diego | California | 92123 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Not listed | Morristown | New Jersey | 07960 | — |
| Not listed | Bismarck | North Dakota | 58501 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Pittsburgh | Pennsylvania | 15241 | — |
| Research Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00362856, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2017 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00362856 live on ClinicalTrials.gov.